Diagnostic Performance of Biomarker-Based Scores As Predictors of Metabolic Dysfunction-Associated Fatty Liver Disease Risk in Healthy Children

Overview

Journal Nutrients

Date 2023 Aug 26

PMID 37630857

Authors

Katarzyna Bergmann

Anna Stefanska

Magdalena Krintus

Lukasz Szternel

Wojciech J Bilinski

Przemyslaw T Paradowski

Grazyna Sypniewska

Affiliations

Soon will be listed here.

Abstract

Introduction: Metabolic dysfunction-associated fatty liver disease (MAFLD)-a new definition for non-alcoholic fatty liver disease-reflects the impact of metabolic abnormalities on liver function. We assessed the diagnostic accuracy of biomarker-based scores for prediction of MAFLD in apparently healthy children.

Methods: This study included 144 children aged 9-11. MAFLD was recognized in 14 girls and 29 boys. Anthropometric indices, glycemia, insulin resistance, lipid profile, enzymes (ALT, AST, GGT, ALP), CRP, -terminal propeptide of type I procollagen (P1NP) and collagen type I C-telopeptide (CTX-1) levels were measured. Fatty liver and hepatic steatosis index (FLI, HSI) and potential indicators of liver fibrogenesis: P1NP/ALP, P1NP/ALPxALT, P1NP/ALPxCRP were calculated.

Results: P1NP/ALPxALT and P1NP/ALPxCRP were significantly higher in subjects with MAFLD. FLI was a good, significant predictor of MAFLD occurrence, regardless of sex. In boys, P1NP/ALPxCRP was a comparable predictor as CRP (OR 1.14 vs. 1.17; < 0.001). P1NP/ALPxCRP had better discrimination capability in boys (AUC = 0.79; < 0.001). However, the use of this algorithm did not improve discriminatory power in comparison to CRP (AUC = 0.81; < 0.001), but gave a better sensitivity for MAFLD prediction (86% vs. 59%).

Conclusions: We suggest that P1NP/ALPXCRP is a reliable tool for MAFLD prediction in routine pediatric practice.

Citing Articles

osteoclast differentiation enhanced by hepatocyte supernatants from high-fat diet mice.

Wang Y, Zhou F, Shu S, Wu Y, Tian H, Li Y Biochem Biophys Rep. 2024; 39:101788.

PMID: 39108622 PMC: 11301062. DOI: 10.1016/j.bbrep.2024.101788.

References

Shashaj B, Luciano R, Contoli B, Morino G, Spreghini M, Rustico C . Reference ranges of HOMA-IR in normal-weight and obese young Caucasians. Acta Diabetol. 2015; 53(2):251-60. DOI: 10.1007/s00592-015-0782-4. View

Veidal S, Vassiliadis E, Bay-Jensen A, Tougas G, Vainer B, Karsdal M . Procollagen type I N-terminal propeptide (PINP) is a marker for fibrogenesis in bile duct ligation-induced fibrosis in rats. Fibrogenesis Tissue Repair. 2010; 3(1):5. PMC: 2860343. DOI: 10.1186/1755-1536-3-5. View

Ferraioli G, Calcaterra V, Lissandrin R, Guazzotti M, Maiocchi L, Tinelli C . Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter. BMC Gastroenterol. 2017; 17(1):61. PMC: 5418679. DOI: 10.1186/s12876-017-0617-6. View

Bilinski W, Szternel L, Siodmiak J, Krintus M, Paradowski P, Domagalski K . Effect of fasting hyperglycemia and insulin resistance on bone turnover markers in children aged 9-11 years. J Diabetes Complications. 2021; 35(10):108000. DOI: 10.1016/j.jdiacomp.2021.108000. View

Eslam M, Alkhouri N, Vajro P, Baumann U, Weiss R, Socha P . Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol. 2021; 6(10):864-873. DOI: 10.1016/S2468-1253(21)00183-7. View

Kim D, Kim W . Nonobese Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016; 15(4):474-485. DOI: 10.1016/j.cgh.2016.08.028. View

Riekki H, Aitokari L, Kivela L, Lahti S, Hiltunen P, Vuorela N . Prevalence and associated factors of metabolic-associated fatty liver disease in overweight Finnish children and adolescents. Front Endocrinol (Lausanne). 2023; 14:1090344. PMC: 10319394. DOI: 10.3389/fendo.2023.1090344. View

Mosca A, Della Volpe L, Alisi A, Veraldi S, Francalanci P, Maggiore G . Non-Invasive Diagnostic Test for Advanced Fibrosis in Adolescents With Non-Alcoholic Fatty Liver Disease. Front Pediatr. 2022; 10:885576. PMC: 9086671. DOI: 10.3389/fped.2022.885576. View

Geserick M, Vogel M, Eckelt F, Schlingmann M, Hiemisch A, Baber R . Children and adolescents with obesity have reduced serum bone turnover markers and 25-hydroxyvitamin D but increased parathyroid hormone concentrations - Results derived from new pediatric reference ranges. Bone. 2019; 132:115124. DOI: 10.1016/j.bone.2019.115124. View

10.

Koot B, van der Baan-Slootweg O, Bohte A, Nederveen A, van Werven J, Tamminga-Smeulders C . Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children. Obesity (Silver Spring). 2013; 21(3):583-90. DOI: 10.1002/oby.20173. View

11.

Papachristodoulou A, Kavvadas D, Karamitsos A, Papamitsou T, Chatzidimitriou M, Sioga A . Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer?. Pediatr Rep. 2021; 13(2):312-321. PMC: 8293345. DOI: 10.3390/pediatric13020039. View

12.

de Silva M, Hewawasam R, Kulatunge C, Chamika R . The accuracy of fatty liver index for the screening of overweight and obese children for non-alcoholic fatty liver disease in resource limited settings. BMC Pediatr. 2022; 22(1):511. PMC: 9426280. DOI: 10.1186/s12887-022-03575-w. View

13.

Vos M, Abrams S, Barlow S, Caprio S, Daniels S, Kohli R . NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology.... J Pediatr Gastroenterol Nutr. 2017; 64(2):319-334. PMC: 5413933. DOI: 10.1097/MPG.0000000000001482. View

14.

Eslam M, Sanyal A, George J . MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology. 2020; 158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. View

15.

Neri C, Scapaticci S, Chiarelli F, Giannini C . Liver Steatosis: A Marker of Metabolic Risk in Children. Int J Mol Sci. 2022; 23(9). PMC: 9100068. DOI: 10.3390/ijms23094822. View

16.

Molleston J, Schwimmer J, Yates K, Murray K, Cummings O, Lavine J . Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr. 2013; 164(4):707-713.e3. PMC: 3962701. DOI: 10.1016/j.jpeds.2013.10.071. View

17.

Zhu C, Huang D, Ma H, Qian C, You H, Bu L . High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol (Lausanne). 2022; 13:848937. PMC: 9128592. DOI: 10.3389/fendo.2022.848937. View

18.

Takahashi Y, Fukusato T . Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014; 20(42):15539-48. PMC: 4229519. DOI: 10.3748/wjg.v20.i42.15539. View

19.

Adeli K, Higgins V, Trajcevski K, White-Al Habeeb N . The Canadian laboratory initiative on pediatric reference intervals: A CALIPER white paper. Crit Rev Clin Lab Sci. 2017; 54(6):358-413. DOI: 10.1080/10408363.2017.1379945. View

20.

Bilinski W, Stefanska A, Szternel L, Bergmann K, Siodmiak J, Krintus M . Relationships between Bone Turnover Markers and Factors Associated with Metabolic Syndrome in Prepubertal Girls and Boys. Nutrients. 2022; 14(6). PMC: 8955753. DOI: 10.3390/nu14061205. View